Novel agents like finerenone are reshaping the cardio–renal–metabolic interface, offering targeted protection for patients with T2DM and CKD, while GLP-1 RAs emerge as intriguing candidates for CV risk reduction, particularly in patients with HFpEF and obesity. This evidence concerns the gene GCG and chronic kidney disease.